Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study

Background: Recent evidence suggests that integrase strand transfer inhibitors are associated with greater weight gain than protease in patients human immunodeficiency virus (HIV-1). Objectives: To describe demographic and clinical characteristics of insured HIV-1 the United States initiating darunavir/?cobicistat/?emtricitabine/?tenofovir alafenamide (DRV/c/FTC/TAF) or bictegravir/FTC/TAF (BIC/FTC/TAF), assess differences body mass index (BMI) change between cohorts up to one year after treatment initiation, identify predictors each treatment. Methods: The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used naïve virologically suppressed stable switchers who initiated DRV/c/FTC/TAF BIC/FTC/TAF (index date) on July 2018, were ?18 years age date, had ?12 months continuous activity pre-index (baseline period). account for baseline characteristics, inverse-probability weighting (IPTW) used. Mean BMI from pre- post-index measurements compared weighted at 3, 6, 9, 12 using mean differences. Predictors ?5% evaluated last measurement, cohort separately. Results: After IPTW, 452 497 included cohorts, respectively. Baseline generally well-balanced (mean age=~50 years, female: ~30%), except type antiretroviral therapy which switched. Patients experienced increases period measurement DRV/c/FTC/TAF, although results only statistically significant 9 (weight: difference=2.50 kg, P=0.005; BMI: difference=0.66 kg/m2, P=0.027). A common predictor among both female gender (DRV/c/FTC/TAF: odds ratio [OR]=5.92, P=0.014; BIC/FTC/TAF: OR=2.00, P<0.001). Conclusion: cohort, reaching statistical significance post-index. Weight is an important factor consider when selecting regimens, since it long-term health consequences. Future studies larger sample size longer follow-up time warranted.